Allergo-immunopathology mechanism of thymol-inhibiting airway remodeling in asthmatic mice by regulating TGF-β/Smad3 pathway.

IF 2.5 4区医学 Q3 ALLERGY Allergologia et immunopathologia Pub Date : 2024-09-01 eCollection Date: 2024-01-01 DOI:10.15586/aei.v52i5.1148

Liyuan Zhang, Wenna Zhang, Yanan Wang, Pei Cai, Chaoran Li, Yan Shi, Seyyed Shamsadin Athari, Ailing Li

{"title":"Allergo-immunopathology mechanism of thymol-inhibiting airway remodeling in asthmatic mice by regulating TGF-β/Smad3 pathway.","authors":"Liyuan Zhang, Wenna Zhang, Yanan Wang, Pei Cai, Chaoran Li, Yan Shi, Seyyed Shamsadin Athari, Ailing Li","doi":"10.15586/aei.v52i5.1148","DOIUrl":null,"url":null,"abstract":"<p><p>Allergic asthma is an important public health problem and is a complicated respiratory sickness that is characterized by bronchial inflammation, bronchoconstriction, and breathlessness. Asthma is orchestrated by type 2 immune response and remodeling is one of the important outputted problem in chronic asthma. Thymol is a naturally occurring monocyclic phenolic, it has a series of biological properties, and its immunomodulatory and anti-remodeling effects on allergic asthma were evaluated. The OVA-LPS-induced asthmatic mice were treated with thymol. Methacholine challenge test, eosinophil count, and levels of IL-4, IL-5, IL-13, and IL-33 in bronchoalveolar lavage fluid, total and OVA-specific IgE levels in serum, remodeling factors, gene expression of TGF-β, Smad2, Smad3, and lung histopathology were done. Treatment with thymol could control AHR, eosinophil percentage levels of Th2 cytokines and Igs, remodeling factors, expression of TGF-β, Smad2 and Smad3 genes, inflammation, goblet cell hyperplasia, and mucus production in asthmatic mice. Thymol can control asthma pathogens and related remodeling and fibrosis bio-factors and can be a potential treatment of asthma.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"52 5","pages":"51-58"},"PeriodicalIF":2.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v52i5.1148","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Allergic asthma is an important public health problem and is a complicated respiratory sickness that is characterized by bronchial inflammation, bronchoconstriction, and breathlessness. Asthma is orchestrated by type 2 immune response and remodeling is one of the important outputted problem in chronic asthma. Thymol is a naturally occurring monocyclic phenolic, it has a series of biological properties, and its immunomodulatory and anti-remodeling effects on allergic asthma were evaluated. The OVA-LPS-induced asthmatic mice were treated with thymol. Methacholine challenge test, eosinophil count, and levels of IL-4, IL-5, IL-13, and IL-33 in bronchoalveolar lavage fluid, total and OVA-specific IgE levels in serum, remodeling factors, gene expression of TGF-β, Smad2, Smad3, and lung histopathology were done. Treatment with thymol could control AHR, eosinophil percentage levels of Th2 cytokines and Igs, remodeling factors, expression of TGF-β, Smad2 and Smad3 genes, inflammation, goblet cell hyperplasia, and mucus production in asthmatic mice. Thymol can control asthma pathogens and related remodeling and fibrosis bio-factors and can be a potential treatment of asthma.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胸腺酚通过调节 TGF-β/Smad3 通路抑制哮喘小鼠气道重塑的异体免疫病理机制

过敏性哮喘是一个重要的公共卫生问题，是一种复杂的呼吸道疾病，以支气管发炎、支气管收缩和呼吸困难为特征。哮喘是由 2 型免疫反应引起的，而重塑是慢性哮喘的重要输出问题之一。百里酚是一种天然单环酚类化合物，具有一系列生物特性，本研究评估了它对过敏性哮喘的免疫调节和抗重塑作用。用胸腺酚治疗 OVA-LPS 诱导的哮喘小鼠。对小鼠进行了甲基胆碱挑战试验、嗜酸性粒细胞计数、支气管肺泡灌洗液中IL-4、IL-5、IL-13和IL-33水平、血清中总IgE和OVA特异性IgE水平、重塑因子、TGF-β、Smad2和Smad3基因表达以及肺组织病理学检查。结果表明，胸腺酚能控制哮喘小鼠的AHR、嗜酸性粒细胞百分比、Th2细胞因子和Igs水平、重塑因子、TGF-β、Smad2和Smad3基因的表达、炎症、上腺细胞增生和粘液分泌。胸腺酚能控制哮喘病原体及相关的重塑和纤维化生物因子，是一种潜在的哮喘治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Allergologia et immunopathologia 医学-过敏

CiteScore

3.70

自引率

0.00%

发文量

131

审稿时长

6-12 weeks

期刊介绍： Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.